SI1720909T1 - Anti-abeta protitelo - Google Patents

Anti-abeta protitelo

Info

Publication number
SI1720909T1
SI1720909T1 SI200531422T SI200531422T SI1720909T1 SI 1720909 T1 SI1720909 T1 SI 1720909T1 SI 200531422 T SI200531422 T SI 200531422T SI 200531422 T SI200531422 T SI 200531422T SI 1720909 T1 SI1720909 T1 SI 1720909T1
Authority
SI
Slovenia
Prior art keywords
abeta
abeta antibody
free
low levels
abeta peptide
Prior art date
Application number
SI200531422T
Other languages
English (en)
Slovenian (sl)
Inventor
Ronald Bradley Demattos
Uma Kuchibhotla
Hsiu-Chiung Yang
Don B Mcclure
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI1720909T1 publication Critical patent/SI1720909T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
SI200531422T 2004-02-23 2005-02-17 Anti-abeta protitelo SI1720909T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody
EP05723280A EP1720909B1 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (1)

Publication Number Publication Date
SI1720909T1 true SI1720909T1 (sl) 2012-01-31

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531422T SI1720909T1 (sl) 2004-02-23 2005-02-17 Anti-abeta protitelo

Country Status (20)

Country Link
US (1) US20070190046A1 (enExample)
EP (1) EP1720909B1 (enExample)
JP (1) JP4851348B2 (enExample)
KR (2) KR20090005410A (enExample)
CN (1) CN1922209B (enExample)
AT (1) ATE534667T1 (enExample)
AU (1) AU2005217596B2 (enExample)
BR (1) BRPI0507856A (enExample)
CA (1) CA2556436C (enExample)
CY (1) CY1112162T1 (enExample)
DK (1) DK1720909T3 (enExample)
EA (1) EA009872B1 (enExample)
ES (1) ES2375627T3 (enExample)
IL (1) IL177611A (enExample)
NO (1) NO20064239L (enExample)
PL (1) PL1720909T3 (enExample)
PT (1) PT1720909E (enExample)
SI (1) SI1720909T1 (enExample)
UA (1) UA93181C2 (enExample)
WO (1) WO2005082939A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
MX2008007477A (es) 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
AU2008204335B2 (en) 2007-01-11 2013-06-13 Michael Bacher Diagnosis and treatment of Alzheimer's and other neurodementing diseases
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2650308A3 (en) * 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2586795B1 (en) 2007-10-05 2018-05-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
AR078986A1 (es) 2009-11-12 2011-12-14 Genentech Inc Un metodo para promover la densidad de espinas dendriticas
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2017200762A2 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
WO2018031334A1 (en) * 2016-08-11 2018-02-15 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP2025506411A (ja) 2022-02-03 2025-03-11 イーライ リリー アンド カンパニー アルツハイマー病の診断及び治療のための局所タウイメージング

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901343T2 (xx) 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
IL151378A0 (en) * 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2318006T3 (es) * 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.

Also Published As

Publication number Publication date
CY1112162T1 (el) 2015-12-09
US20070190046A1 (en) 2007-08-16
EP1720909A2 (en) 2006-11-15
CA2556436A1 (en) 2005-09-09
JP2008500279A (ja) 2008-01-10
BRPI0507856A (pt) 2007-07-10
IL177611A (en) 2013-05-30
WO2005082939A2 (en) 2005-09-09
CN1922209B (zh) 2012-09-05
ES2375627T3 (es) 2012-03-02
DK1720909T3 (da) 2012-01-30
UA93181C2 (ru) 2011-01-25
IL177611A0 (en) 2006-12-10
KR100889430B1 (ko) 2009-03-23
JP4851348B2 (ja) 2012-01-11
NO20064239L (no) 2006-11-20
AU2005217596A1 (en) 2005-09-09
ATE534667T1 (de) 2011-12-15
CN1922209A (zh) 2007-02-28
EA200601545A1 (ru) 2007-02-27
EA009872B1 (ru) 2008-04-28
CA2556436C (en) 2014-04-01
WO2005082939A3 (en) 2005-10-27
KR20090005410A (ko) 2009-01-13
AU2005217596B2 (en) 2012-01-19
PT1720909E (pt) 2011-12-23
PL1720909T3 (pl) 2012-04-30
EP1720909B1 (en) 2011-11-23
KR20060126785A (ko) 2006-12-08

Similar Documents

Publication Publication Date Title
PL1720909T3 (pl) Przeciwciało anty-abeta
MX2018005512A (es) Agentes de union de esclerostina.
MY174493A (en) Binding agents
IL244803B (en) Human anti-beta antibodies and their use
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон&#39;югати та способи їх застосування
CU24058B1 (es) Antagonistas de pcsk9
TW200732349A (en) Anti-OX40L antibodies and methods using same
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
MX341064B (es) Variantes de la familia il-1.
EA200700702A1 (ru) Аналоги локсапина и способы их применения
EA200800601A1 (ru) Связывающие fas антитела
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13
UA97231C2 (ru) Изолированное антитело, которое специфически связывается с il-6, композиция, которая его содержит, и его применение
UY28629A1 (es) Procedimiento para preparar triamidas de ácido trimesínico dendríticas